1st Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$700,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform TRIPS Waiver General patent issues Issues related to pharmaceutical intellectual property (IP)

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
ART MOTTA New Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)
CAROLINE QUAT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

H.R. 1350, Camerons Law H.R. 5376 - Share the Savings with Seniors Act S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023. Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
ART MOTTA New Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)
CAROLINE QUAT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2673 (118th), H.R. 5376 (118th), S. 866 (118th), H.R. 1350 (118th)

Health Issues HCR

H.R.7085 Biosecure Act H.R. 5539/S.3131 ORPHAN Cures Act, expanding orphan drug exclusion in IRA H.R.5378, the LOWER COSTS, MORE TRANSPARENCY ACT, In Senate - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (Better Act), Pharmacy Benefit Manager Reform Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties Patent listings of drug-device combinations Reauthorization of newborn screening programs Reauthorization of the pediatric priority review voucher program RSV Vaccine issues FDA modernization policy issues Medicare drug price negotiation Medicaid Drug Rebate Program proposed rule PBM Reform (misc. bills) Issues related to reform of pharmacy benefit managers Issues related to FDA proposed regulation of lab developed tests Issues related to the orphan drug exclusion of the Inflation Reduction Act Issues related to the price and manufacture of inhaled medicines Issues related to march-in rights Issues related to drug pricing Issues related to importation of drugs Sustainability issues as a general topic General issues related to health equity in rare disease and clinical trials General issues related to diagnostics for patients with rare diseases General issues related to rare disease and orphan drugs

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
ART MOTTA New Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)
CAROLINE QUAT —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 7085 (118th), S. 3131 (118th), H.R. 5378 (118th), H.R. 5539 (118th)

Medicare/Medicaid MMM

H.R. 5539 Orphan Cures Act, (expanding orphan drug exclusion in IRA) H.R. 3876 Access to Genetic Counselor Services Act of 2023 H.R. 2666 Medicaid VBPs for Patients Act H.R. 5539 Orphan Cures Act, (expanding orphan drug exclusion in IRA) Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No 117-169) Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure Centers for Medicare and Medicaid Innovation (CMMI) policy issues Value-based payment arrangements Medicare patient access to rare disease therapies, Part B and Part D drugs Medicaid Drug Rebate Program proposed rule, specifically the stacking rule Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies General issues related to diagnostic reimbursement Value-based payment arrangements Efforts to improve coding, coverage, and access for rare disease therapies

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
ART MOTTA New Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)
CAROLINE QUAT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3876 (118th), H.R. 5376 (118th), H.R. 5539 (118th), H.R. 2666 (118th)

Pharmacy PHA

Issues related to Pharmacy Benefit Managers (PBMs) Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169)

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
ART MOTTA New Policy Advisor and Floor Assistant, Rep. Eric Swalwell (CA-15) Legislative Assistant, Rep. Eric Swalwell (CA-15) Legislative Aide, Rep. Eric Swalwell (CA-15)
CAROLINE QUAT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.